DECISION OF THE ATHLETICS INTEGRITY UNIT
IN THE CASE OF MS ANNA RAMONA PAPAIOANNOU

INTRODUCTION

1. World Athletics has established the Athletics Integrity Unit ("AIU") whose role is to protect the integrity of the sport of Athletics, including fulfilling World Athletics' obligations as a Signatory to the World Anti-Doping Code ("the "Code"). World Athletics has delegated implementation of the World Athletics Anti-Doping Rules ("ADR") to the AIU, including but not limited to the following activities in relation to International-Level Athletes: Testing, Investigations, Results Management, Hearings, Sanctions and Appeals.

2. Ms Anna Ramona Papaioannou ("the Athlete") is a 32-year-old sprinter from Cyprus\(^1\).

3. This decision is issued by the AIU pursuant to Rule 8.5.6 ADR, which provides as follows:

   "8.5.6 In the event that the Athlete or other Person either (i) admits the violation and accepts the proposed Consequences or (ii) is deemed to have admitted the violation and accepted the Consequences as per Rule 8.5.2(f), the Integrity Unit will promptly:

   (a) issue a decision confirming the commission of the violation(s) and the imposition of the specified Consequences (including, if applicable, a justification for why the maximum potential sanction was not imposed);

   (b) Publicly Report that decision in accordance with Rule 14;

   (c) send a copy of the decision to the Athlete or other Person and to any other party that has a right, further to Rule 13, to appeal the decision (and any such party may, within 15 days of receipt, request a copy of the full case file pertaining to the decision)."

THE ATHLETE’S COMMISSION OF ANTI-DOPING RULE VIOLATIONS

4. Rule 2 ADR sets out that the following shall constitute an Anti-Doping Rule Violation:

   "2.1 Presence of a Prohibited Substance or its Metabolites or Markers in an Athlete’s Sample

   […]

   2.2 Use or Attempted Use by an Athlete of a Prohibited Substance or a Prohibited Method”

5. On 14 June 2021, the Athlete provided a urine Sample, In-Competition, at the ‘Filothei Women Gala’ held in Athens, Greece, which was given code 0025489 (the “Sample”).

\(^1\) https://www.worldathletics.org/athletes/cyprus/ramona-papaioannou-14263288
6. On 8 December 2021, the World Anti-Doping Agency (“WADA”) accredited laboratory in Bucharest, Romania (the “Bucharest Laboratory”) reported an Adverse Analytical Finding in the Sample for the presence of Testosterone and its Metabolites consistent with exogenous origin (the “Adverse Analytical Finding”).

7. The AIU reviewed the Adverse Analytical Finding in accordance with Article 5 of the International Standard for Results Management (“ISRM”) and determined that:

7.1. the Athlete did not have a Therapeutic Use Exemption (“TUE”) that had been granted (or that would be granted) for the Testosterone an its metabolites found in the Sample; and

7.2. there was no apparent departure from the International Standard for Testing and Investigations (“ISTI”) or from the International Standard for Laboratories (“ISL”) that could reasonably have caused the Adverse Analytical Finding.

8. Therefore, on 13 January 2022, the AIU notified the Athlete of the Adverse Analytical Finding in accordance with Article 5.1.2.1 of the ISRM, including that the Adverse Analytical Finding may result in Anti-Doping Rule Violations pursuant to Rule 2.1 ADR and/or Rule 2.2 ADR and of the imposition of an immediate Provisional Suspension.

9. The Athlete was also informed of her rights, inter alia, to request the B Sample analysis, to request copies of the laboratory documentation supporting the Adverse Analytical Finding and to admit the Anti-Doping Rule Violations and potentially benefit from a one-year reduction in the period of Ineligibility pursuant to Rule 10.8.1 ADR.

10. On 20 January 2022, the Athlete explained that following an injury she had not participated in Athletics for two (2) years and in summer 2021 attempted to make a comeback to the sport. The Athlete asserted that she had failed to declare a number of supplements on the Doping Control Form for the Sample collected on 14 June 2021 and that she believed the Adverse Analytical Finding had been caused by the use of one or more of these supplements. Although the Athlete stated that, on this basis, she did not believe that she had intentionally taken any prohibited substances, she accepted and admitted that Anti-Doping rule Violations had been committed, waived her right to the B Sample analysis and accept the period of Ineligibility specified by the AIU.

11. On 31 January 2022, the AIU received an Admission of Anti-Doping Rule Violations and Acceptance of Consequences Form signed by the Athlete.

CONSEQUENCES

12. This is the Athlete’s first Anti-Doping Rule Violation.

---

2 specifically, Androsterone, Etiocholanolone, 5α-androstane-3α,17 diol (“5αAdiol”) and 5β-androstane-3α,17 diol (“5βAdiol”)

3 The GC/C/IRMS analysis was performed by the WADA-accredited laboratory in Madrid, Spain (the “Madrid Laboratory”).
13. Rule 10.2 ADR specifies that the period of Ineligibility for an Anti-Doping Rule Violation under Rule 2.1 or Rule 2.2 shall be as follows:

“10.2.1 Save where Rule 10.2.4 applies, the period of Ineligibility will be four years where:

(a) The anti-doping rule violation does not involve a Specified Substance or a Specified Method, unless the Athlete or other Person can establish that the anti-doping rule violation was not intentional.

(b) The anti-doping rule violation involves a Specified Substance or a Specified Method and the Integrity Unit can establish that the anti-doping rule violation was intentional.”

14. Testosterone (when administered exogenously) is a Prohibited Substance under the WADA 2021 Prohibited List under the category S1.1 Anabolic Androgenic Steroids (AAS). It is a Non-Specified Substance prohibited at all times.

15. The period of Ineligibility to be imposed is therefore a period of four (4) years, unless the Athlete demonstrates that the Anti-Doping Rule Violations were not intentional.

16. The Athlete has not demonstrated that the Anti-Doping Rule Violations were not intentional. Therefore, the mandatory period of Ineligibility is a period of Ineligibility of four (4) years.

17. However, Rule 10.8.1 ADR provides that an athlete potentially subject to an asserted period of Ineligibility of four (4) years may benefit from a one (1)-year reduction in the period of Ineligibility based on an early admission and acceptance of sanction:

“10.8.1 One year reduction for certain anti-doping rule violations based on early admission and acceptance of sanction.

Where the Integrity Unit notifies an Athlete or other Person of an anti-doping rule violation charge that carries an asserted period of Ineligibility of four (4) or more years (including any period of Ineligibility asserted under Rule 10.4), if the Athlete or other Person admits the violation and accepts the asserted period of Ineligibility no later than 20 days after receiving the Notice of Charge, the Athlete or other Person may receive a one (1) year reduction in the period of Ineligibility asserted by the Integrity Unit. Where the Athlete or other Person receives the one (1) year reduction in the asserted period of Ineligibility under this Rule 10.8.1, no further reduction in the asserted period of Ineligibility will be allowed under any other Rule.”

18. The Athlete was notified of the Adverse Analytical Finding and that this may result in Anti-Doping Rule Violations under Rule 2.1 and/or Rule 2.2 and a period of Ineligibility of four (4) years on 13 January 2022.

19. On 20 January 2022, the Athlete admitted the Anti-Doping Rule Violations and stated that she accepted the asserted period of Ineligibility and on 31 January 2022, she returned the Admission of Anti-Doping Rule Violations and Acceptance of Consequences Form signed.

---

4 This Notice of Allegation of Anti-Doping Rule Violations was issued to the Athlete in accordance with Article 5.1.2 of the ISRM, prior to a Notice of Charge issued in accordance with Article 7 of the ISRM.
20. The Athlete shall therefore receive a one (1) year reduction in the asserted period of Ineligibility pursuant to Rule 10.8.1 based on an early admission and acceptance of sanction.

21. On the basis that the Athlete has admitted the Anti-Doping Rule Violations under Rule 2.1 ADR and Rule 2.2 ADR, in accordance with Rule 10.2.1 ADR and the application of Rule 10.8.1 ADR, the AIU confirms by this decision the following Consequences for a first Anti-Doping Rule Violation:

21.1. a period of Ineligibility of three (3) years commencing on 13 January 2022 (the date of Provisional Suspension); and

21.2. disqualification of the Athlete's results on and since 14 June 2021, with all resulting Consequences, including the forfeiture of any titles, awards, medals, points prizes and appearance money.

22. The Athlete has accepted the above Consequences for her Anti-Doping Rule Violations and has expressly waived her right to have those Consequences determined by the Disciplinary Tribunal at a hearing.

PUBLICATION

23. In accordance with Rule 8.5.6(b) ADR, the AIU shall publicly report this decision on the AIU's website.

RIGHTS OF APPEAL

24. This decision constitutes the final decision of the AIU pursuant to Rule 8.5.6 ADR.

25. Further to Rule 13.2.3 ADR, WADA and the Cyprus Anti-Doping Authority (“CyADA”) have a right of appeal against this decision to the Court of Arbitration for Sport in Lausanne, Switzerland, in accordance with the procedure set out at Rule 13.6.1 ADR.

26. If an appeal is filed against this decision by WADA or CyADA, the Athlete will be entitled to exercise her right of cross-appeal in accordance with Rule 13.2.4 ADR.

Monaco, 4 February 2022